中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

临床试验阶段抗HBV新药的研究现状

李强 黄玉仙 陈良

李强, 黄玉仙, 陈良. 临床试验阶段抗HBV新药的研究现状[J]. 临床肝胆病杂志, 2016, 32(2): 370-373. DOI: 10.3969/j.issn.1001-5256.2016.02.038
引用本文: 李强, 黄玉仙, 陈良. 临床试验阶段抗HBV新药的研究现状[J]. 临床肝胆病杂志, 2016, 32(2): 370-373. DOI: 10.3969/j.issn.1001-5256.2016.02.038
Li Qiang, Huang YuXian, Chen Liang. Current studies of novel drugs against hepatitis B virus in clinical trials[J]. J Clin Hepatol, 2016, 32(2): 370-373. DOI: 10.3969/j.issn.1001-5256.2016.02.038
Citation: Li Qiang, Huang YuXian, Chen Liang. Current studies of novel drugs against hepatitis B virus in clinical trials[J]. J Clin Hepatol, 2016, 32(2): 370-373. DOI: 10.3969/j.issn.1001-5256.2016.02.038

临床试验阶段抗HBV新药的研究现状

DOI: 10.3969/j.issn.1001-5256.2016.02.038
详细信息
  • 中图分类号: R512.62

Current studies of novel drugs against hepatitis B virus in clinical trials

  • 摘要: 慢性乙型肝炎(CHB)是肝硬化和肝癌的常见病因之一。干扰素与核苷和核苷酸类药物能够有效控制病情,但HBs Ag清除率或血清学转换率极低,大多数患者会在停药后复发。近年来,随着HBV-宿主相互作用机制研究的不断深入,产生了许多有望成功治愈CHB的新药。综述了处于临床试验Ⅰ、Ⅱ、Ⅲ阶段的抗HBV新药,认为抗HBV新药已初步显示出令人欣喜的前景。

     

  • [1]European Association for The Study of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
    [2]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int,2015,35(Suppl 1):78-81.
    [3]KAO JH.HBeA g-positive chronic hepatitis B:why do I treat my patients with pegylated interferon?[J].Liver Int,2014,34(1):112-119.
    [4]BUTI M.HBeA g-positive chronic hepatitis B:why do i treat my patients with nucleos(t)ide analogs?[J].Liver Int,2014,34(1):108-111.
    [5]BAM RA,YANT SR,CIHLAR T.Tenofovir alafenamide is not a substrate for renal organic anion transporters(OATs)and does not exhibit OAT-dependent cytotoxicity[J].Antivir Ther,2014,19(7):687-692.
    [6] AGARWAL K,FUNG SK,NGUYEN TT,et al.Twenty eight day safety and efficacy of tenofovir alafenamide(TAF)fumarate in chronic hepatitis B(CHB)patients[C]//64th annual meeting and postgraduate course of the American Association for the Study of Liver Diseases.Washington,DC,2013.
    [7]AGARWAL K,FUNG SK,NGUYEN TT,et al.Twenty-eight day safety,antiviral activity,and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection[J].J Hepatol,2015,62(3):533-540.
    [8]YUEN MF,KIM J,KIM CR,et al.A randomized placebo-controlled,dose-finding study of oral LB80380 in HBeA g-positive patients with chronic hepatitis B[J].Antivir Ther,2006,11(8):977-983.
    [9]LAI CL,AHN SH,LEE KS,et al.Phase IIb multicentred randomised trial of besifovir(LB80380)versus entecavir in Asian patients with chronic hepatitis B[J].Gut,2014,63(6):996-1004.
    [10]YUEN MF,AHN SH,LEE KS,et al.Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs.entecavir:results from a multicentre study[J].J Hepatol,2015,62(3):526-532.
    [11]JIANG M,BROERING R,TRIPPLER M,et al.Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J].J Viral Hepat,2014,21(12):860-872.
    [12]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.
    [13]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,54(6):426-432.
    [14]XU DZ,WANG XY,SHEN XL,et al.Results of a phaseⅢclinical trial with an HBsA g-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients:experiences and findings[J].J Hepatol,2013,59(3):450-456.
    [15]VOLZ T,ALLWEISS L,BEN MM,et al.The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J].J Hepatol,2013,58(5):861-867.
    [16]HAEFELI WE,BLANK,MIKUS G,et al.Successful first administration of Myrcludex B,a first-in-class Hepatitis B and D Virus entry inhibitor,in humans[C]//63rd annual meeting of the American Association for the Study of Liver Diseases(AASLD).Boston,MA,2012.
    [17]BOGOMOLOV P,VORONKOVA N,ALLWEISS L,et al.A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B[C]//49th annual meeting of the European Association for the Study of the Liver(EASL).Britain,2014.
    [18]BREZILLON N,BRUNELLE MN,MASSINET H,et al.Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Albu PA/SCID mice[J].PLoS One,2011,6(12):e25096.
    [19]WU G,LIU B,ZHANG Y,et al.Preclinical characterization of GLS4,an inhibitor of hepatitis B virus core particle assembly[J].Antimicrob Agents Chemother,2013,57(11):5344-5354.
    [20]WANG XY,WEI ZM,WU GY,et al.In vitro inhibition of HBV replication by a novel compound,GLS4,and its efficacy against adefovirdipivoxil-resistant HBV mutations[J].Antivir Ther,2012,17(5):793-803.
    [21]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a potent HBsA g release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B[C]//61st annual meeting of the American Association for the Study of Liver Diseases.Boston,MA,2010.
    [22]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a potent HBsA g release inhibitor that elicits durable immunological control of chronic HBV infection[C]//62nd annual meeting of the American Association for the Study of Liver Diseases(AASLD).San Francisco,CA,2011.
    [23]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a second generation HBsA g release inhibitor with improved tolerability[C]//63rd annual meeting of the American Association for the Study of Liver Diseases(AASLD).Boston,MA,2012.
    [24]WOODDELL CI,ROZEMA DB,HOSSBACH M,et al.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection[J].Mol Ther,2013,21(5):973-985.
    [25]YUEN MF,CHAN H,GIVEN B,et al.PhaseⅡ,dose ranging study of ARC-520,a siRNA-based therapeutic,in patients with chronic hepatitis B virus infection[C]//49th annual meeting of the European Association for the Study of the Liver(EASL).Britain,2014.
    [26]SEIGAL BA,CONNORS WH,FRALEY A,et al.The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library,and their optimization to give lead compounds with in vivo antitumor activity[J].J Med Chem,2015,58(6):2855-2861.
    [27]EBERT G,ALLISON C,PRESTON S,et al.Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J].Proc Natl Acad Sci U S A,2015,112(18):5803-5808.
    [28]GAGGAR A,COESHOTT C,APELIAN D,et al.Safety,tolerability and immunogenicity of GS-4774,a hepatitis B virus-specific therapeutic vaccine,in healthy subjects:a randomized study[J].Vaccine,2014,32(39):4925-4931.
    [29]REN XW,XU WR,ZOU MX,et al.A Compound elvucitabine pharmaceutical composition and its preparation method and uses:CN102652748A[P].2012-09-05.(in Chinese)任晓文,徐为人,邹美香,等.稳定的艾夫他滨药物组合物及其制备方法:CN102652748A[P].2012-09-05.
    [30] LIM SG,LEE KS,CHUANG WL,et al.Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection:48 week analysis of a phase 2 study[J].J Clin Virol,2006,36(2):231-238.
    [31]REDDY KR,MATELICH MC,UGARKAR BG,et al.Pradefovir:a prodrug that targets adefovir to the liver for the treatment of hepatitis B[J].J Med Chem,2008,51(3):666-676.
    [32]IYER RK,MARQUIS J,HARTER M,et al.Preclinical studies of SB9200 for hepatitis treatment[C]//34th annual meeting of the American College of Toxicology.San Antonio,TX,2014.
    [33]CUNNINGHAM ME,WRIGHT JD,PANDEY RK,et al.Pan-genotypic anti-HCV activity of SB 9200 assessed in the'capture-fusion'replication assay[C]//64th annual meeting and postgraduate course of the American Association for the Study of Liver Diseases.Washington,DC,2013.
    [34] SPELLMAN M,MARTIN JT.Treament of chronic hepatitis B infection with DV-601,a therapeutic vaccine[C]//46th annual meeting of the European Association for the Study of the Liver(EASL).Berlin,2011.
    [35]FELD JJ,COLLEDGE D,SOZZI V,et al.The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging[J].Antiviral Res,2007,76(2):168-177.
    [36]BENGSCH B,MARTIN B,THIMME R.Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].J Hepatol,2014,61(6):1212-1219.
    [37]SHERMAN AC,TREHANPATI N,DAUCHER M,et al.Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir[J].AIDS Res Hum Retroviruses,2013,29(4):665-672.
  • 加载中
计量
  • 文章访问数:  2219
  • HTML全文浏览量:  3
  • PDF下载量:  567
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-07-29
  • 出版日期:  2016-02-20
  • 刊出日期:  2016-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回